Ross Miller
Public Health & General Preventive Medicine · Beverly Hills, CANPI 1134209794
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $39,640 of the $64,968 with a category attached, or 61.0%. It is spread thinly across 30 manufacturers, the largest accounting for just 16.2%. Reporting peaked in 2021 at $14,631 and has fallen 60.5% since, to $5,782 in 2025. Among public health & general preventive medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $656.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$11K
- Novo Nordisk$8K
- Gilead$7K
- Boehringer Ingelheim International GmbH$6K
- Gen-probe, Inc.$6K
- Vertex$5K
- plus $22K from 24 others
What the payments were for
- Consulting fees$39,64061%
- Speaking & faculty fees$16,08225%
- Travel & lodging$5,8759%
- Food & beverage$2,8884%
- Education$4841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 7 | $10,528 |
| Novo Nordisk | 29 | $8,018 |
| Gilead | 2 | $7,400 |
| Boehringer Ingelheim International GmbH | 2 | $6,250 |
| Gen-probe, Inc. | 4 | $5,761 |
| Vertex | 1 | $5,200 |
| Alkermes, Inc. | 4 | $5,061 |
| Boehringer Ingelheim | 4 | $4,942 |
| Biogen | 2 | $3,710 |
| Shield Therapeutics Inc | 4 | $3,194 |
| Genentech USA, Inc. | 1 | $1,575 |
| Urovant Sciences Inc | 2 | $1,047 |
| Hologic Sales And Service, LLC | 2 | $542 |
| Dr.reddy's Laboratories,inc. | 1 | $350 |
| Sanofi-aventis U.S. LLC | 9 | $303 |
| Jazz Pharmaceuticals Inc. | 6 | $233 |
| Novartis | 3 | $156 |
| Boston Scientific | 1 | $142 |
| Neurocrine Biosciences, Inc. | 2 | $81 |
| Sanofi | 2 | $81 |
| Sumitomo Pharma America, Inc. | 2 | $74 |
| Aerie Pharmaceuticals, Inc. | 1 | $58 |
| GSK | 1 | $47 |
| MDD US Operations, LLC | 1 | $45 |
| Verrica Pharmaceuticals Inc. | 1 | $41 |
| CMP Pharma, Inc. | 1 | $32 |
| Lilly USA, LLC | 1 | $30 |
| Heartflow, Inc. | 1 | $30 |
| Smith+Nephew | 1 | $25 |
| USA Angelalign Technology CORP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Aptima$3,507
- ACCRUFER$3,156
- NONE$2,500
- SPINRAZA$1,750
- Non-Covered Product$1,575
- GEMTESA$965
- BTX$507
- Hydroxychloroquine Sulfate$350
- Apollo ESG NXT System$142
How this compares
$64,968 in reported general payments places this provider in the 95th percentile of 109 public health & general preventive medicine providers in California.
See all public health & general preventive medicine providers in California →
Other public health & general preventive medicine in Beverly Hills
- Steven GalsonThousand Oaks$594K
- Ryan ZaneSan Bernardino$97K
- Daniel CosgroveIndian Wells$61K
- Philp DarneySan Francisco$13K
- Karen StuderLoma Linda$9K
- George RutherfordSan Francisco$9K
- Kate HaggertySan Marcos$8K
- Serena TonstadLoma Linda$5K
- Michael Criquila Jolla$3K
- Douglas FryeLos Angeles$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.